{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T12:23:22Z","timestamp":1777638202861,"version":"3.51.4"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T00:00:00Z","timestamp":1727136000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005416","name":"Research Council of Norway","doi-asserted-by":"publisher","award":["223250"],"award-info":[{"award-number":["223250"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010377","name":"National Institute for Health and Care Excellence","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010377","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000269","name":"UK Research and Innovation Economic and Social Research Council","doi-asserted-by":"publisher","award":["ES\/Y007514\/1"],"award-info":[{"award-number":["ES\/Y007514\/1"]}],"id":[{"id":"10.13039\/501100000269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cancer Policy"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.jcpo.2024.100507","type":"journal-article","created":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T01:52:23Z","timestamp":1727315543000},"page":"100507","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Analysis of factors associated with use of real-world data in single technology appraisals of cancer drugs by the National Institute for Health and Care Excellence"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1587-9674","authenticated-orcid":false,"given":"Jiyeon","family":"Kang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Cairns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcpo.2024.100507_bib1","unstructured":"National Institute for Health and Care Excellence (NICE). NICE strategy 2021 to 2026: Dynamic, Collaborative, Excellent. 2021;"},{"key":"10.1016\/j.jcpo.2024.100507_bib2","unstructured":"National Institute for Health and Care Excellence (NICE). NICE real-world evidence framework [Internet]. 2022. Available from: www.nice.org.uk\/corporate\/ecd9."},{"issue":"1","key":"10.1016\/j.jcpo.2024.100507_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41746-020-0277-8","article-title":"Translating evidence into practice: eligibility criteria fail to eliminate clinically significant differences between real-world and study populations","volume":"3","author":"Averitt","year":"2020","journal-title":"npj Digit Med"},{"key":"10.1016\/j.jcpo.2024.100507_bib4","article-title":"Real world data in health technology assessment of complex health technologies","volume":"13","author":"Hogervorst","year":"2022","journal-title":"Front Pharm. [Internet]"},{"key":"10.1016\/j.jcpo.2024.100507_bib5","unstructured":"Bell H., Wailoo A.J., Hernandez M., Grieve R., Faria R., Gibson L., et al. The use of real world data for the estimation of treatment effects in NICE decision making report by the Decision Support Unit [Internet]. 2016. Available from: www.nicedsu.org.uk."},{"key":"10.1016\/j.jcpo.2024.100507_bib6","unstructured":"National Insitute for Health and Care Excellence (NICE). TA855 Mobocertinib for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy [Internet]. 2023. Available from: https:\/\/www.nice.org.uk\/guidance\/ta855."},{"issue":"4","key":"10.1016\/j.jcpo.2024.100507_bib7","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1017\/S0266462320000434","article-title":"Real-world evidence use in assessments of cancer drugs by NICE","volume":"36","author":"Bullement","year":"2020","journal-title":"Int J. Technol. Assess. Health Care [Internet]"},{"issue":"10","key":"10.1016\/j.jcpo.2024.100507_bib8","article-title":"Evaluation of US oncology electronic health record real-world data to reduce uncertainty in health technology appraisals: a retrospective cohort study","volume":"13","author":"Mpofu","year":"2023","journal-title":"BMJ Open [Internet]"},{"issue":"1","key":"10.1016\/j.jcpo.2024.100507_bib9","article-title":"Real-world data from expanded access programmes in health technology assessments: a review of NICE technology appraisals","volume":"12","author":"Polak","year":"2022","journal-title":"BMJ Open [Internet]"},{"issue":"12","key":"10.1016\/j.jcpo.2024.100507_bib10","doi-asserted-by":"crossref","first-page":"S465","DOI":"10.1016\/j.jval.2022.09.2309","article-title":"RWD84 the role of real-world evidence in cell and gene therapy regulatory and health technology assessment decisions","volume":"25","author":"Honig","year":"2022","journal-title":"Value Heal [Internet]"},{"key":"10.1016\/j.jcpo.2024.100507_bib11","doi-asserted-by":"crossref","DOI":"10.1002\/cpt.2914","article-title":"Effectively leveraging RWD for external controls: a systematic literature review of regulatory & HTA decisions","author":"Sola-Morales","year":"2023","journal-title":"Clin. Pharm. Ther. [Internet]"},{"issue":"1","key":"10.1016\/j.jcpo.2024.100507_bib12","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/cpt.2480","article-title":"Use of real-world evidence to drive drug development strategy and inform clinical trial design","volume":"111","author":"Dagenais","year":"2022","journal-title":"Clin. Pharm. Ther. [Internet]"},{"issue":"1","key":"10.1016\/j.jcpo.2024.100507_bib13","article-title":"Protocol for data extraction: how real-world data have been used in the National Institute for Health and Care Excellence appraisals of cancer therapy","volume":"12","author":"Kang","year":"2022","journal-title":"BMJ Open [Internet]"},{"issue":"11","key":"10.1016\/j.jcpo.2024.100507_bib14","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s12325-018-0805-y","article-title":"Interpretation and impact of real-world clinical data for the practicing clinician","volume":"35","author":"Blonde","year":"2018","journal-title":"Adv. Ther. [Internet]"},{"issue":"Supplement_7","key":"10.1016\/j.jcpo.2024.100507_bib15","doi-asserted-by":"crossref","first-page":"vii54","DOI":"10.1093\/rheumatology\/key109","article-title":"Randomized controlled trials and real-world data: differences and similarities to untangle literature data","volume":"57","author":"Monti","year":"2018","journal-title":"Rheumatol. [Internet]"},{"key":"10.1016\/j.jcpo.2024.100507_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcpo.2023.100424","article-title":"The role of real-world data and evidence in oncology medicines approved in EU in 2018\u20132019","volume":"36","author":"Eskola","year":"2023","journal-title":"J. Cancer Policy"},{"key":"10.1016\/j.jcpo.2024.100507_bib17","series-title":"Improving economic evaluation and decision-making for oncology drugs using real-world data [Internet]","author":"Kang","year":"2023"},{"key":"10.1016\/j.jcpo.2024.100507_bib18","doi-asserted-by":"crossref","unstructured":"Tai T.A., Latimer N.R., Benedict A., Kiss Z., Nikolaou A. Prevalence of Immature Survival Data for Anti-Cancer Drugs Presented to the National Institute for Health and Care Excellence and Impact on Decision Making. Value Heal. 2020 Dec 8;","DOI":"10.1016\/j.jval.2020.10.016"},{"issue":"3","key":"10.1016\/j.jcpo.2024.100507_bib19","article-title":"Cross-sectional analysis of use of real-world data in single technology appraisals of oncological medicine by the National Institute for Health and Care Excellence in 2011\u20132021","volume":"14","author":"Kang","year":"2024","journal-title":"BMJ Open [Internet]"},{"issue":"12","key":"10.1016\/j.jcpo.2024.100507_bib20","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.pmrj.2009.10.004","article-title":"The problem of multiple testing","volume":"1","author":"Sainani","year":"2009","journal-title":"PM R. [Internet]"},{"key":"10.1016\/j.jcpo.2024.100507_bib21","article-title":"Multiple hypothesis testing in experimental economics","author":"List","year":"2016","journal-title":"Artefact. F. Exp. [Internet]"},{"key":"10.1016\/j.jcpo.2024.100507_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/jpps.2023.11460","article-title":"Integration of real-world evidence from different data sources in health technology assessment [Internet]","volume":"Vol. 26","author":"Graili","year":"2023","journal-title":"J. Pharm. Pharm. Sci."},{"key":"10.1016\/j.jcpo.2024.100507_bib23","doi-asserted-by":"crossref","first-page":"5569","DOI":"10.3389\/fonc.2021.695936","article-title":"Application of real-world data to external control groups in oncology clinical trial drug development","volume":"11","author":"Yap","year":"2022","journal-title":"Front Oncol."},{"key":"10.1016\/j.jcpo.2024.100507_bib24","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2147\/CLEP.S242097","article-title":"Synthetic and external controls in clinical trials \u2013 a primer for researchers","volume":"12","author":"Thorlund","year":"2020","journal-title":"Clin. Epidemiol. [Internet]"},{"issue":"2","key":"10.1016\/j.jcpo.2024.100507_bib25","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jval.2021.08.013","article-title":"Approaches for enhanced extrapolation of long-term survival outcomes using electronic health records of patients with cancer","volume":"25","author":"Wang","year":"2022","journal-title":"Value Heal"},{"issue":"6","key":"10.1016\/j.jcpo.2024.100507_bib26","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1177\/0272989X12472398","article-title":"Survival analysis for economic evaluations alongside clinical trials\u2014extrapolation with patient-level data","volume":"33","author":"Latimer","year":"2013","journal-title":"Med Decis. Mak. [Internet]"},{"key":"10.1016\/j.jcpo.2024.100507_bib27","unstructured":"Faria R., Alava M.H., Manca A., Wailoo A.J., Uk WWNO. NICE DSU technical support document 17: The use of observational data to inform estimates of treatment effectiveness in technology appraisal: Methods for comparative individual patient data reported by the Decision Support Unit [Internet]. 2015. Available from: \u3008www.nicedsu.org.uk\u3009."},{"key":"10.1016\/j.jcpo.2024.100507_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.jval.2022.01.014","article-title":"The (Harsh) reality of real-world data external comparators for health technology assessment","author":"Cox","year":"2022","journal-title":"Value Health [Internet]"},{"issue":"8","key":"10.1016\/j.jcpo.2024.100507_bib29","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1111\/cts.13315","article-title":"Treatment effectiveness in a rare oncology indication: lessons from an external control cohort study","volume":"15","author":"Oksen","year":"2022","journal-title":"Clin. Transl. Sci. [Internet]"},{"key":"10.1016\/j.jcpo.2024.100507_bib30","first-page":"1","article-title":"Don\u2019t think twice, it\u2019s all right\u201d: using additional data to reduce uncertainty regarding oncologic drugs provided through managed access agreements in England","author":"Kang","year":"2022","journal-title":"Pharm. - Open"},{"issue":"7","key":"10.1016\/j.jcpo.2024.100507_bib31","doi-asserted-by":"crossref","first-page":"A429","DOI":"10.1016\/j.jval.2013.08.607","article-title":"Do nice evidence review groups (ERG) focus on different aspects of manufacturer submissions in oncology?","volume":"16","author":"Heemstra","year":"2013","journal-title":"Value Heal [Internet]"},{"issue":"6","key":"10.1016\/j.jcpo.2024.100507_bib32","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1586\/17512433.2015.1088382","article-title":"Clinical trial design for rare cancers - why a less conventional route may be required","volume":"8","author":"Panageas","year":"2015","journal-title":"Expert Rev. Clin. Pharm. [Internet]"},{"key":"10.1016\/j.jcpo.2024.100507_bib33","unstructured":"National institute for health and care excellence (NICE). Developing NICE guidelines: the manual - appendix H: Appraisal checklists, evidence tables, GRADE and economic profiles [Internet]. 2022. Available from: \u3008http:\/\/www.bristol.ac.uk\/media-library\/sites\/social-community-medicine\/robis\/robisguidancedocument.pdfAmstarwww.amstar.caDSUNMAmethodologychecklisthttp:\/\/nicedsu.org.uk\/wp-content\/uploads\/2016\/03\/TSD7-reviewer-checklist.final_.08.05.12.pdf\u3009."},{"key":"10.1016\/j.jcpo.2024.100507_bib34","series-title":"Understanding Regression Analysis","first-page":"176","article-title":"The problem of multicollinearity [Internet]","author":"Allen","year":"2004"}],"container-title":["Journal of Cancer Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213538324000419?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213538324000419?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T13:28:31Z","timestamp":1732627711000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213538324000419"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":34,"alternative-id":["S2213538324000419"],"URL":"https:\/\/doi.org\/10.1016\/j.jcpo.2024.100507","relation":{},"ISSN":["2213-5383"],"issn-type":[{"value":"2213-5383","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analysis of factors associated with use of real-world data in single technology appraisals of cancer drugs by the National Institute for Health and Care Excellence","name":"articletitle","label":"Article Title"},{"value":"Journal of Cancer Policy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcpo.2024.100507","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100507"}}